Literature DB >> 1935026

SCID-PANSS: two-tier diagnostic system for psychotic disorders.

S R Kay1, L A Opler, R L Spitzer, J B Williams, A Fiszbein, A Gorelick.   

Abstract

The SCID-PANSS was developed as a two-tier diagnostic system for psychotic disorders to supplement categorical diagnosis with functional-dimensional assessment. The procedure combines the DSM-III-R Structured Clinical Interview and Rating Criteria (SCID) with those from the Positive and Negative Syndrome Scale (PANSS). The comprehensive 50- to 60-minute interview yields diagnostic classification, plus a profile of 30 symptoms and 10 dimensional scales, including positive and negative syndromes, depression, thought disturbance, and severity of illness. A study of 34 psychotic inpatients assessed by five psychiatrists showed strong interrater correlations (0.85 to 0.97 for summary scales, P less than .0001), supporting the reliability of the SCID-PANSS for clinical and research applications.

Entities:  

Mesh:

Year:  1991        PMID: 1935026     DOI: 10.1016/0010-440x(91)90085-q

Source DB:  PubMed          Journal:  Compr Psychiatry        ISSN: 0010-440X            Impact factor:   3.735


  11 in total

1.  Two subgroups of schizophrenia identified by systematic cognitive neuropsychiatric mapping.

Authors:  István Szendi; Mihály Racsmány; Csongor Cimmer; Gábor Csifcsák; Zoltán Ambrus Kovács; György Szekeres; Gabriella Galsi; Ferenc Tóth; Attila Nagy; Edit Anna Garab; Krisztina Boda; Gergely Gulyás; József Géza Kiss; József Dombi; Csaba Pléh; Zoltán Janka
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-10-15       Impact factor: 5.270

2.  Identification of candidate single-nucleotide polymorphisms in NRXN1 related to antipsychotic treatment response in patients with schizophrenia.

Authors:  Aaron Jenkins; José A Apud; Fengyu Zhang; Heather Decot; Daniel R Weinberger; Amanda J Law
Journal:  Neuropsychopharmacology       Date:  2014-03-14       Impact factor: 7.853

3.  Heterogeneity of Treatment Effects of Long-Acting Injectable Antipsychotic Medications.

Authors:  T Scott Stroup; Natalie A Bareis; Robert A Rosenheck; Marvin S Swartz; Joseph P McEvoy
Journal:  J Clin Psychiatry       Date:  2018-11-27       Impact factor: 4.384

4.  Automatic language analysis identifies and predicts schizophrenia in first-episode of psychosis.

Authors:  Alicia Figueroa-Barra; Daniel Del Aguila; Mauricio Cerda; Pablo A Gaspar; Lucas D Terissi; Manuel Durán; Camila Valderrama
Journal:  Schizophrenia (Heidelb)       Date:  2022-06-01

5.  Examination of heterogeneity in treatment response to antipsychotic medications.

Authors:  Natalie Bareis; T Scott Stroup
Journal:  Schizophr Res       Date:  2019-08-01       Impact factor: 4.939

6.  Looking at the other side of the coin: a meta-analysis of self-reported emotional arousal in people with schizophrenia.

Authors:  Katiah Llerena; Gregory P Strauss; Alex S Cohen
Journal:  Schizophr Res       Date:  2012-10-03       Impact factor: 4.939

7.  Comparison of the effects of Sertindole and Olanzapine on Cognition (SEROLA): a double-blind randomized 12-week study of patients diagnosed with schizophrenia.

Authors:  René Ernst Nielsen; Florence Odur; Torben Ostergaard; Povl Munk-Jørgensen; Jimmi Nielsen
Journal:  Ther Adv Psychopharmacol       Date:  2014-02

8.  Therapeutic alliance in early schizophrenia spectrum disorders: a cross-sectional study.

Authors:  Ragnhild Johansen; Valentina C Iversen; Ingrid Melle; Knut A Hestad
Journal:  Ann Gen Psychiatry       Date:  2013-05-09       Impact factor: 3.455

9.  Reduced erythrocyte membrane polyunsaturated fatty acid levels indicate diminished treatment response in patients with multi- versus first-episode schizophrenia.

Authors:  Nana Li; Ping Yang; Mimi Tang; Yong Liu; Wenbin Guo; Bing Lang; Jianjian Wang; Haishan Wu; Hui Tang; Yan Yu; Xiangxin Wu; Cuirong Zeng; Ting Cao; Hualin Cai
Journal:  Schizophrenia (Heidelb)       Date:  2022-02-25

10.  Cariprazine in the treatment of schizophrenia: a proof-of-concept trial.

Authors:  Suresh Durgam; Robert E Litman; Kelly Papadakis; Dayong Li; György Németh; István Laszlovszky
Journal:  Int Clin Psychopharmacol       Date:  2016-03       Impact factor: 1.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.